{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-059298","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2021-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.744946+00:00","generated_at":"2026-06-28T03:52:11.468425+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AbCellera appoints Neil Aubuchon as Chief Commercial Officer","bullets":["Neil Aubuchon named CCO effective December 2, 2021; will lead commercial strategy and partnership evaluation.","Aubuchon brings over 20 years experience from Amgen, Lilly, and Santen, including global marketing roles.","CEO Carl Hansen cited Aubuchon's commercial experience as key to expanding AbCellera's deal structures."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-059298","json":"https://secwatch.observer/filing/0001564590-21-059298.json","markdown":"https://secwatch.observer/filing/0001564590-21-059298.md","text":"https://secwatch.observer/filing/0001564590-21-059298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021059298/0001564590-21-059298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021059298/abcl-8k_20211202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:52:11.468425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}